Main Article Content
Clinical evaluation of indoramin as the sole agent for the treatment of hypertension
Abstract
An open-ended clinical trial of Indoramin (WY-21901), a new antihypertensive agent with both a-adrenergic blocking and cardio-inhibitory properties, was conducted on a group of 27 patients with mild or moderate essential hypertension. Blood pressures, erect and supine, were effectively lowered. In 70% of the patients the mean standing diastolic pressures were well controlled. Heart rate was not significantly lowe.red. Side-effects occurred in 80% of patients, but did not persist in most of them. Severe side-effects, necessitating withdrawal of Indoramin, were experienced by one-third of the patients. Proteinuria was observed in 3 patients and a slightly elevated serum urea in 1. No other biochemical tests were abnormal.
S. Afr. Med. J., 48, 1569 (1974)
S. Afr. Med. J., 48, 1569 (1974)